BioPorto <ul><li>at a glance  </li></ul><ul><li>NGAL will emerge as the kidney’s equivalent to the heart Troponin, and mil...
Quote of the years..... <ul><li>CEO Roy Zwanziger of Alere - who paid 1,6 BILLION US dollars for Biosite when asked about ...
AKI - Acute Kidney Injury,  fact: Killer of Millions - every year... <ul><li>14 million patients develop AKI every year*  ...
NGAL  (Neutrophil Gelatinase-Associated Lipocalin) The Biomarker that gives precise information, fast and inexpensively, i...
BioPorto has The NGAL Test & the immaterial rights (patent) ! <ul><li>BioPorto  has developed the Worlds FIRST and so far ...
Economics  <ul><li>Pricetag for The  NGAL  test expected to be 7-15 € for each test * </li></ul><ul><li>Distribution will ...
Challenges, things to overcome.. <ul><li>Negotiations with  EPO (European Patent Organisation) according to  BioPorto  min...
Valuation <ul><li>Recent Coverage initiated by independent and wellrespected Nordic Bio Investor (NBI)*  says fair value p...
FAQ -  why so inexpensive  ??? <ul><li>In Denmark there is in the stockmarket generally mistrust towards the biotech-secto...
Recommendation <ul><li>In my book - it’s a Strong Buy !  </li></ul><ul><li>Finally - again - my favourite Quote from CEO R...
Disclaimer:  <ul><li>The Author Stengaard and associates owns shares in BioPorto  - Safe Harbor Statement </li></ul><ul><l...
Upcoming SlideShare
Loading in …5
×

Bioporto at a glance. A Medicoinvestor presentation

3,101 views

Published on

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
3,101
On SlideShare
0
From Embeds
0
Number of Embeds
1,764
Actions
Shares
0
Downloads
0
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Bioporto at a glance. A Medicoinvestor presentation

  1. 1. BioPorto <ul><li>at a glance </li></ul><ul><li>NGAL will emerge as the kidney’s equivalent to the heart Troponin, and millions of lives will be saved.... </li></ul>
  2. 2. Quote of the years..... <ul><li>CEO Roy Zwanziger of Alere - who paid 1,6 BILLION US dollars for Biosite when asked about the price: </li></ul><ul><li>“ ... I would say that if NGAL comes in reasonable, Biosite was a very cheap acquisition ...” </li></ul>
  3. 3. AKI - Acute Kidney Injury, fact: Killer of Millions - every year... <ul><li>14 million patients develop AKI every year* - and the number is rising fast. Of those affected 4 million patients die, and countless others suffer from lasting effects of AKI </li></ul><ul><li>Rapid help is double help - only until now no effective “ early warning system” have been available... If AKI is treated - expensive dialysis or even more expense kidney transplantation could be avoided for a large number of patients who suffer from the lasting effects of AKI </li></ul><ul><li>Because no effective marker has been on the market, no therapies that could help those suffering from AKI have been developed. Hence there has been almost no breakthrough in treatment of AKI since the 1950‘es (contrary to Heart Failure - thanks to the marker - Troponin) </li></ul><ul><li>The Worldmarket is up for grabs if you provide doctors with the right information at the right time (Window of opportunity) </li></ul><ul><li>* the number of patients does NOT include China, India, Russia, Brazil and developing countries </li></ul>
  4. 4. NGAL (Neutrophil Gelatinase-Associated Lipocalin) The Biomarker that gives precise information, fast and inexpensively, in Intensive Care Units or Emergency Rooms <ul><li>NGAL is a protein, that rises sharply is the Kidney is distressed </li></ul><ul><li>NGAL gives reliable, precise, speedy and definitive information about the state of the Kidney, so that proper and effective action can be taken - immediately </li></ul><ul><li>NGAL is measured with a simple Test - in blood, urine or plasma, in the Central Laboratories of the hospitals RA( Random access) or at bedside in the ICU’s or ER’s - called POC (Point of Care) testing </li></ul><ul><li>NGAL Test gives results in 10 minutter, only 2 hours after the Kidney has been damaged. (The present “gold standard” test used Serume Creatine gives less reliable results and only after 48-72 hours) NGAL test is highly recommended by experts Worldwide* </li></ul><ul><li>* www.singhealthacademy.com.sg Dr. Khurana 2012 - NGAL has several characteristics of an ideal biomarker </li></ul>
  5. 5. BioPorto has The NGAL Test & the immaterial rights (patent) ! <ul><li>BioPorto has developed the Worlds FIRST and so far ONLY 1-step test (known as a homogeneous test), a test that can be used (after small alterations) in virtually all central laboratory systems. </li></ul><ul><li>BioPorto has the ONLY valid patent defining the cutoff-value showing AKI (all other patents have been revoked/annulled *) </li></ul><ul><li>BioPorto is presently finalising distribution agreements and license agreements (companies such as - but not limited to - Roche, Siemens, Abbott, Alere, Daheter, Olympus amongst others ..**) </li></ul><ul><li>The Worldmarket is expected to be between 2-300 million test on a yearly basis in 2021. BioPorto expects to get the Lions share </li></ul><ul><li>*late 2011 the patent used by Abbott/Alere was revoked by EPO ** according to BioPorto statements found on their website </li></ul>
  6. 6. Economics <ul><li>Pricetag for The NGAL test expected to be 7-15 € for each test * </li></ul><ul><li>Distribution will probably take 50% ** </li></ul><ul><li>Production is probably less than or around 1 € per test *** </li></ul><ul><li>Minimum earnings for BioPorto will be 2,5 € per test </li></ul><ul><li>Earnings from direct sales and from license agreements (upfront payments and royalties) </li></ul><ul><li>The Worldmarket is covered by the Patent (except the US where USPTO is presently examining it) </li></ul><ul><li>* info from BioPorto presentation, ** / *** estimate based on “normal” rates </li></ul>
  7. 7. Challenges, things to overcome.. <ul><li>Negotiations with EPO (European Patent Organisation) according to BioPorto minor adjustments, Oppositions demands revokement - oral proceedings 7. february 2012. </li></ul><ul><li>Even if the patent should be revoked (unlikely) BioPorto will still have the only 1-step test on the market (and a head start of +3 years) </li></ul><ul><li>Conclusion of finalisation of Distributions agreement with major diagnostic companies like Roche/Siemens/Abbott/Daheter/Alere et al. , and License agreements (based on the existing agreement with american Instrumentation Lab) </li></ul><ul><li>Limited funds. BioPorto points out there is sufficient funds available to finalise the study the FDA (Federal Drug Agency) demands prior to permitting sale in US , nonetheless funds are limited </li></ul><ul><li>Taking on the Worldmarket requires a coordinated effort, so it is vital that BioPorto signs agreements with the major Diagnostic companies </li></ul>
  8. 8. Valuation <ul><li>Recent Coverage initiated by independent and wellrespected Nordic Bio Investor (NBI)* says fair value presently is 16,7 Dkr - share price today 7,5 - 8,0 Dkr. - </li></ul><ul><li>MarketCap is around 350 million Dkr (approximately 45 million euro) - on a medium term (3-5 years) it looks as a ten-bagger... </li></ul><ul><li>BioPorto trades at the Copenhagen Stock Exchange (NasdaqOMX) - ticker BIOPOR.CO </li></ul><ul><li>BioPorto is still totally unknown on the Worldmarket, this will inevitably change with global distribution of The NGAL Test. </li></ul><ul><li>* please go to www.Nordicbioinvestor.com for more info </li></ul>
  9. 9. FAQ - why so inexpensive ??? <ul><li>In Denmark there is in the stockmarket generally mistrust towards the biotech-sector and most investors mistake BioPorto for a Biotech-company. BioPorto is a actually diagnostic company and should be priced as such (lower risk) </li></ul><ul><li>Because of the importance of the patent, it has been fiercely opposed by major diagnostic companies, BioPorto has won all cases so far, but market is still doubtfull </li></ul><ul><li>Uncertainty regarding the patent situation have prolonged signing of distribution agreements </li></ul><ul><li>Prospects of developing companies at this day and age is generally negative, however recent multicenter-studies and experts worldwide recommend the NGAL Test as the new “Gold Standard” * </li></ul><ul><li>* http://www.cli-online.com/featured-articles/is-ngal-the-troponin-of-the-kidney/index.html </li></ul>
  10. 10. Recommendation <ul><li>In my book - it’s a Strong Buy ! </li></ul><ul><li>Finally - again - my favourite Quote from CEO Roy Zwanziger of Alere - who paid 1,6 BILLION US dollars for Biosite when asked about the price for Biosite: </li></ul><ul><li>“ I would say that if NGAL comes in reasonable, Biosite was a very cheap acquisition .” </li></ul><ul><li>But then - that was before his (CCH’s) patent was revoked </li></ul><ul><li>Read more about NGAL / BioPorto at: www.Bioporto.com or www.ngal.com </li></ul>
  11. 11. Disclaimer: <ul><li>The Author Stengaard and associates owns shares in BioPorto - Safe Harbor Statement </li></ul><ul><li>This non-confidentiel abstract contains forward looking statements. including an estimate of future businessopportunities for BioPorto. In this abstract I present data about product already developed and products still under development .The presentation also contains estimates for the total Global market, price estimates and the economis results. A more throrough presentation with more detailed information is available from stengaard at medicoinvestor.com upon request. Future results may deviate from the prognosis, The progress and development of BioPorto may differ from my description in this paper. Changes may occur due to legal issues, material and immaterial disputes, capital requirements, changes in therapies and diagnostic tools - amongst other posibilities . In other words - these are my own estimates, and I cannot be held accountable if this changes (positively or negatively) </li></ul>

×